Search results for "ORPHAN DRUG|Designated|Treatment of Relapsed/Refractory Follicular Lymphoma" in comments (approximate match)
Showing 1 - 2 of 2 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Zanubrutinib (formerly known as BGB-3111) was developed by BeiGene as a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). The drug forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. ...
